# Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

> **NCT04395079** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Malignant Female Reproductive System Neoplasm
- Platinum-Resistant Malignant Female Reproductive System Neoplasm
- Recurrent Malignant Female Reproductive System Neoplasm
- Refractory Malignant Female Reproductive System Neoplasm

## Interventions

- **BIOLOGICAL:** Durvalumab
- **RADIATION:** Internal Radiation Therapy
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT04395079
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-07
- **Primary completion:** 2024-10-11
- **Final completion:** 2026-12-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395079, "Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04395079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*